EUVIMEDEUVIMED entdecken
Crossref

15‐color highly sensitive flow cytometry assay for post anti‐CD19 targeted therapy ( anti‐CD19‐CAR‐T and blinatumomab) measurable residual disease assessment in B‐lymphoblastic leukemia/lymphoma: Real‐world applicability and challenges

Gaurav Chatterjee iD, Priyanka Dhende, Simpy Raj, Vruksha Shetty, Sitaram Ghogale, Nilesh Deshpande, Karishma Girase, Jagruti Patil, Aastha Kalra, Gaurav Narula iD, Kajal Dalvi, Chetan Dhamne und 7 weitere

European Journal of Haematology · 2024-01 · 112 (1) · 122-136

DOI: 10.1111/ejh.14102 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, online erschienen am 14.09.2023. Verfasst von Gaurav Chatterjee und 18 weiteren Autor:innen. Beteiligte Einrichtung: Hematopathology Laboratory, ACTREC, Tata Memorial Center, HBNI University, Navi Mumbai, Maharashtra, India. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Antibodies, Bispecific, Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: National Cancer Grid, Tata Memorial Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Measurable residual disease (MRD) is the most relevant predictor of disease‐free survival in B‐cell acute lymphoblastic leukemia (B‐ALL). We aimed to establish a highly sensitive flow cytometry (MFC)‐based B‐ALL‐MRD (BMRD) assay for patients receiving anti‐CD19 immunotherapy with an alternate gating approach and to document the prevalence and immunophenotype of recurrently occurring low‐level mimics and confounding populations.

Methods

We standardized a 15‐color highly‐sensitive BMRD assay with an alternate CD19‐free gating approach. The study included 137 MRD samples from 43 relapsed/refractory B‐ALL patients considered for anti‐CD19 immunotherapy.

Results

The 15‐color BMRD assay with CD22/CD24/CD81/CD33‐based gating approach was routinely applicable in 137 BM samples and could achieve a sensitivity of 0.0005%. MRD was detected in 29.9% (41/137) samples with 31.7% (13/41) of them showing

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenAntibodies, BispecificBurkitt LymphomaPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaHumansFlow CytometryEndothelial CellsAntigens, CD19Neoplasm, Residual

Stichwörter der Autor:innen

B-ALL MRD post anti-CD19 immunotherapyhigh-sensitivity flow cytometrymimics and artifacts

Substanzen

blinatumomabReceptors, Chimeric AntigenAntigens, CD19Antibodies, Bispecific

Autor:innen und Institutionen

  • Hematopathology Laboratory, ACTREC, Tata Memorial Center, HBNI University, Navi Mumbai, Maharashtra, India.
  • Department of Pediatric Oncology, Tata Memorial Center, Mumbai, Mumbai, Maharashtra, India.
  • Hematopathology Laboratory, Tata Memorial Center, Mumbai, Mumbai, Maharashtra, India.

ORCID-Profile: Gaurav Chatterjee, Gaurav Narula, Sweta Rajpal, Nikhil V Patkar, Papagudi G Subramanian, Prashant R Tembhare

Förderung

  • National Cancer Grid, Tata Memorial Centre

Zitieren

APA

Chatterjee, G., Dhende, P., Raj, S., Shetty, V., Ghogale, S., Deshpande, N., Girase, K., Patil, J., Kalra, A., Narula, G., Dalvi, K., Dhamne, C., Moulik, N. R., Rajpal, S., Patkar, N. V., Banavali, S., Gujral, S., Subramanian, P. G., & Tembhare, P. R. (2024). 15‐color highly sensitive flow cytometry assay for post anti‐CD19 targeted therapy ( anti‐CD19‐CAR‐T and blinatumomab) measurable residual disease assessment in B‐lymphoblastic leukemia/lymphoma: Real‐world applicability and challenges. European Journal of Haematology, 112(1), 122-136. https://doi.org/10.1111/ejh.14102

Vancouver

Chatterjee G, Dhende P, Raj S, Shetty V, Ghogale S, Deshpande N, et al. 15‐color highly sensitive flow cytometry assay for post anti‐CD19 targeted therapy ( anti‐CD19‐CAR‐T and blinatumomab) measurable residual disease assessment in B‐lymphoblastic leukemia/lymphoma: Real‐world applicability and challenges. European Journal of Haematology. 2024;112(1):122-136. doi:10.1111/ejh.14102

BibTeX
@article{Chatterjee2024,
  author = {Chatterjee, Gaurav and Dhende, Priyanka and Raj, Simpy and Shetty, Vruksha and Ghogale, Sitaram and Deshpande, Nilesh and Girase, Karishma and Patil, Jagruti and Kalra, Aastha and Narula, Gaurav and Dalvi, Kajal and Dhamne, Chetan and Moulik, Nirmalya Roy and Rajpal, Sweta and Patkar, Nikhil V and Banavali, Shripad and Gujral, Sumeet and Subramanian, Papagudi G and Tembhare, Prashant R},
  title = {15‐color highly sensitive flow cytometry assay for post anti‐CD19 targeted therapy ( anti‐CD19‐CAR‐T and blinatumomab) measurable residual disease assessment in B‐lymphoblastic leukemia/lymphoma: Real‐world applicability and challenges},
  journal = {European Journal of Haematology},
  year = {2024},
  volume = {112},
  number = {1},
  pages = {122--136},
  doi = {10.1111/ejh.14102}
}
Kostenlos starten →